DESCRIPTION
Each mL of Sodium Sulfacetamide Lotion, 10% contains 100 mg of sodium sulfacetamide in a vehicle consisting of edetic acid, hydroxyethyl cellulose, lauramide DEA, methylparaben, PEG-400 monolaurate, propylene glycol, purified water, silicone emulsion, sodium chloride, sodium metabisulfite, and xanthan gum.

Sodium sulfacetamide is a sulfonamide with antibacterial activity. Chemically, sodium sulfacetamide is N' -[(4-amino phenyl) sulfonyl] - acetamide, monosodium salt, monohydrate. The structural formula is:

\[
\text{\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{structure.png}
\caption{Structure of Sodium Sulfacetamide}
\end{figure}}
\]

CLINICAL PHARMACOLOGY
The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, based on sulfonamides acting as a competitive inhibitor of para-aminobenzoic acid (PABA) utilization, an essential component for bacterial growth. While absorption through intact skin in humans has not been determined, in vitro studies with human cadaver skin indicated a percutaneous absorption of about 4%. Sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine largely unchanged. The biological half-life has been reported to be between 7 to 13 hours.

The pharmacokinetics of sulfacetamide and its major metabolite sulfanilamide in Sodium Sulfacetamide Lotion was evaluated in adult subjects (N=14) with acne vulgaris. The subjects applied Sodium Sulfacetamide Lotion to their face, back, chest, and shoulders every 12 hours for 28 days. The percentage of the applied dose of Sodium Sulfacetamide Lotion excreted in the urine as sulfacetamide plus sulfanilamide ranged from 0.08 to 0.33%.

INDICATIONS
Sodium Sulfacetamide Lotion is indicated in the topical treatment of acne vulgaris.

CONTRAINDICATIONS
Sodium Sulfacetamide Lotion is contraindicated for use by patients having known hypersensitivity to sulfonamides or any other component of this preparation (see WARNINGS).

WARNINGS
Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Hypersensitivity reactions may occur when a sulfonamide is readministered, irrespective of the route of administration. Sensitivity reactions have been reported in individuals with no prior history of sulfonamide hypersensitivity. At the first sign of hypersensitivity, skin rash, or other reactions, discontinue use of this preparation (see ADVERSE REACTIONS).

Sodium Sulfacetamide Lotion contains sodium metabisulfite, a sulfite that may cause allergic-type
reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people (see CONTRAINDICATIONS).

**PRECAUTIONS**

**General**

For external use only. Keep away from eyes. If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. Hypersensitivity reactions may occur when a sulfonamide is readministered irrespective of the route of administration, and cross-sensitivity between different sulfonamides may occur. Sodium sulfacetamide can cause reddening and scaling of the skin. Particular caution should be employed if areas of involved skin to be treated are denuded or abraded.

**Keep out of reach of children.**

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Animal reproduction studies have not been conducted with Sodium Sulfacetamide Lotion. It is also not known whether Sodium Sulfacetamide Lotion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide Lotion should be given to a pregnant woman only if clearly needed.

Kernicterus may occur in the newborn as a result of treatment of a pregnant woman at term with orally administered sulfonamide. There are no adequate and well-controlled studies of Sodium Sulfacetamide Lotion in pregnant women, and it is not known whether topically applied sulfonamides can cause fetal harm when administered to a pregnant woman.

**Nursing Mothers**

It is not known whether sodium sulfacetamide is excreted in human milk following topical use of Sodium Sulfacetamide Lotion. Systemically administered sulfonamides are capable of producing kernicterus in the infants of lactating women. Small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. Because many drugs are excreted in human milk, caution should be exercised in prescribing for nursing women.

**Pediatric Use**

Safety and effectiveness in pediatric patients under the age of 12 have not been established.

**ADVERSE REACTIONS**

In controlled clinical trials for the management of *acne vulgaris*, the occurrence of adverse reactions associated with the use of Sodium Sulfacetamide Lotion was infrequent and restricted to local events. The total incidence of adverse reactions reported in these studies was less than 2%. Only one of 105 patients treated with Sodium Sulfacetamide Lotion had adverse reactions of erythema, itching, and edema. It has been reported that sodium sulfacetamide may cause local irritation, stinging, and burning. While the irritation may be transient, occasionally the use of medication has to be discontinued.

To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

**DOSAGE AND ADMINISTRATION**
Apply a thin film to affected areas twice daily.

**HOW SUPPLIED**

4 fl oz (118 mL) Bottles NDC 68682-010-04

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Shake well before using. Keep tightly closed.

**Distributed by:**
Oceanside Pharmaceuticals, a division of Bausch Health US, LLC
Bridgewater, NJ 08807 USA

**Manufactured by:**
Bausch Health Companies Inc.
Laval, Quebec H7L 4A8, Canada

© 2019 Bausch Health Companies Inc. or its affiliates

9473903
Revised 05/2019

**PRINCIPAL DISPLAY PANEL - 118 mL Bottle Carton**

NDC 68682-010-04

Rx only

Sodium Sulfacetamide

Lotion, 10%

FOR TOPICAL USE ONLY

SHAKE WELL BEFORE USING

One 4 fl oz

(118 mL) Bottle

OCEANSIDE PHARMACEUTICALS
**SODIUM SULFACETAMIDE**

sodium sulfacetamide lotion

---

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:68682-010</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMAN PRESCRIPTION DRUG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOPICAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>sulfacetamide sodium</td>
<td>sulfacetamide sodium</td>
<td>100 mg in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDETIC ACID</td>
<td></td>
</tr>
<tr>
<td>HYDROXYETHYL CELLULOSE (2000 MPA.S AT 1%)</td>
<td></td>
</tr>
<tr>
<td>POLYETHYLENE GLYCOL 400</td>
<td></td>
</tr>
<tr>
<td>LAURIC DIETHANOLAMIDE</td>
<td></td>
</tr>
</tbody>
</table>
methylparaben (UNII: A21BC7H9T)
sodium chloride (UNII: 451W471Q8X)
sodium metabisulfite (UNII: 4VON5FNS3C)
water (UNII: 059QF0KO0R)
xanthan gum (UNII: TTV12P4NEE)

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:68682-010-04</td>
<td>1 in 1 CARTON</td>
<td>12/18/2015</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>118 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA authorized generic</td>
<td>NDA019931</td>
<td>12/18/2015</td>
<td></td>
</tr>
</tbody>
</table>

Labeler - Oceanside Pharmaceuticals (832011691)

Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bausch Health Companies, Inc.</td>
<td>245141858</td>
<td>MANUFACTURE(68682-010) , PACK(68682-010) , LABEL(68682-010)</td>
<td></td>
</tr>
</tbody>
</table>

Revised: 5/2019